Anti-angiogenesis treatment improves hearing in some NF2 patients

...ccessful NF2 treatment not involving surgery or radiation. "This kind of treatment response is unprecedented," says Scott Plotkin, MD, PhD, of the pappas Center for Neuro-Oncology in the MGH Cancer Center, lead author of the NEJM paper. "Our study is the first to provide evidence that a drug can shrink...

Drug Shows Promise in Nervous-System Tumor Treatment

...estored. This improvement also lasted for up to 16 months. "This kind of treatment response is unprecedented," lead author Dr. Scott Plotkin of the pappas Center for Neuro-Oncology in the MGH Cancer Center, said in a news release. "Our study is the first to provide evidence that a drug can shrink vestibu...

SANYO Donates Systems Effective vs. Flu to United Nations Organization Affiliate - World Association of Former United Nations Internes and Fellows (WAFUNIF)

.... There are already locations in New York that are using this cutting-edge technology. Two units are currently in use at the Office of Nurse Mary pappas at St. Francis Preparatory in Fresh Meadows, Queens, and The Mary Louis Academy (TMLA) in Jamaica Estates, NY. Other units have also been donated and ...

TYRX Appoints David Elliot, Jr. Chief Operating Officer

...anted in over 1,200 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers , The State University of New Jersey. Addi...

TYRX, Inc. Announces 1,000th Implant of AIGISRx(TM) Anti-Bacterial Envelope

...anted in over 1,100 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers , The State University of New Jersey. Addi...

CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development

...enter clinical development in 2009 for wake promotion. About CoLucid Pharmaceuticals, Inc. CoLucid Pharmaceuticals was founded in December 2005 by pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. ...

Statewide Gambling Conference -- Series of 'Firsts' -- Begins 9-30-08

...counselors. A limited number of scholarships are still available, for details and more information please e-mail us at ccgofpa@aol.com or call Jim pappas at: 215- 389-4008. MEDIA PARTICIPATION IS WELCOMED ...

CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound

...id Pharmaceuticals was founded in December 2005 by pappas Ventures to advance innovative drug candidates wit...please visit http://www.carecapital.com . About pappas Ventures pappas Ventures is a Research Triangle Park, North Caroli...

Advanced Instruments' Anoxomat Mark II Anaerobic System is Excellent Alternative to Anaerobic Chambers, Gas Bags in Clinical Laboratories

...ined with the well-known reproducibility of these conditions, gives microbiologists a strong tool to draw accurate conclusions from repeated findings, pappas said. The Anoxomat Mark II Anaerobic System is immediately available from Spiral Biotech. For more information, reach Advanced Instruments or Spiral...

Mother's Day Gives Woman Reason to Celebrate Life's Most Precious Gift

...y and honor for mothers everywhere. But for Yancey pappas of Woodstock, Ga., the coming of Mother's Day was nearly not a cause for celebration. pappas was diagnosed at age 18 with a rare liver disease....recious gifts, a baby boy or girl. A year later, pappas learned from her gynecologist that she had polycys...

Pappas in Medical Technology

TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry

...anted in over 3,000 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers , The State University of New Jersey. Addi...

Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008

...OL-144, using an oral formulation," added Dr. Pilgrim. About CoLucid Pharmaceuticals, Inc. CoLucid Pharmaceuticals was founded in December 2005 by pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. ...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

...y held company based in Cambridge, Massachusetts, Cequent was established in 2006 with seed funding from Ampersand Ventures, New England Partners, and pappas Ventures. For more information, visit http://www.cequentpharma.com About the AACR The mi...

Nanotubes used for first time to send signals to nerve cells

...Engineering and one of the study's senior authors. pappas and UTMB research associate Anton Liopo collaborat... two types of functionalized nanotubes we tested," pappas said. "Next we want to find a way to functionalize...se surfaces more biocompatible." Another avenue pappas wants to explore is finding out whether nanotubes ...

Pappas in Biological Technology

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

...tor improved hearing and led to tumor shrinkage in some patients," said Scott R. Plotkin, M.D., Ph.D., director of the Neurofibromatosis Clinic at the pappas Center for Neuro-Oncology in the Massachusetts General Hospital Cancer Center. "If shown to be efficacious, we believe that its oral administration a...

SANYO Donates Air Purification Systems Effective Against Flu Viruses to New York Airports and Schools

...dports at JFK and LaGuardia Airports the first to use this cutting-edge technology. One unit has already been donated to the Office of Nurse Mary pappas at St. Francis Preparatory in Fresh Meadows, Queens. The next unit will be donated to The Mary Louis Academy (TMLA) in Jamaica Estates, NY. TMLA is a ...

Spiral Biotech to Introduce New Autoplate Spiral Plating System at ASM General Meeting in May

...ugh, and ensures no sample-to-sample contamination. "Altogether, the new Autoplate drives spiral plating technology a generational leap forward," pappas said. The new Autoplate deposits microbial suspensions without the need for most serial dilutions, thus increasing efficiency in the microbiology...

CeNeRx BioPharma Completes $15 Million Series B Financing

... investors Aisling Capital, L Capital Partners and pappas Ventures participated in the funding round. CeNeRx..., visit http://www.lcapitalpartners.com . About pappas Ventures pappas Ventures is a Research Triangle Park, North Caroli...

Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman

...iences Fund) will join Anthera's Board of Directors. The financing also included existing investors VantagePoint Venture Partners, Sofinnova Ventures, pappas Ventures and Mitsubishi International Corporation. In addition, the company announced the appointment of Christopher S. Henney as Chairman of the Bo...

REVISED: BrainCells Inc. Expands Series B Financing to $50 Million

...ion. Other investors that participated in the Series B included MedImmune Ventures, Bay City Capital, Oxford Bioscience Partners, Technology Partners, pappas Ventures and NeuroVentures. The financing will be used to continue clinical development of BCI's product candidates including a Phase 2 trial with BCI...

BrainCells Inc. Expands Series B Financing to $50 Million

...ated in the extension. Other investors that participated in the Series B included MedImmune Ventures, Oxford Bioscience Partners, Technology Partners, pappas Ventures and NeuroVentures. The financing will be used to continue clinical development of BCI's product candidates including a Phase 2 trial with BCI...

BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing

...f its Series B financing. New investor MedImmune Ventures joined previous investors Bay City Capital, Oxford Bioscience Partners, Technology Partners, pappas Ventures and Neuro Ventures in the round. The financing will be used to continue clinical development of BCI's product candidates including BCI-540, a...

Optherion, Inc. Completes $37 Million Start Up Financing

...ociates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA, and GE Healthcare Financial Services, Chicago, IL. Colin J. Foster, Opt...